SMT202000095T1 - Formulazioni di anticorpi anti-sclerostina ad alta concentrazione - Google Patents

Formulazioni di anticorpi anti-sclerostina ad alta concentrazione

Info

Publication number: SMT202000095T1
Authority: SM; San Marino
Prior art keywords: high concentration; antibody formulations; sclerostin antibody; concentration anti; sclerostin
Prior art date: 2010-05-14

Application number

SM20200095T

Other languages

English (en)

Inventor

Timothy D Osslund

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-05-14

Filing date

2011-05-10

Publication date

2020-03-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT202000095(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-10 Application filed by Amgen Inc filed Critical Amgen Inc

2020-03-13 Publication of SMT202000095T1 publication Critical patent/SMT202000095T1/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SM20200095T 2010-05-14 2011-05-10 Formulazioni di anticorpi anti-sclerostina ad alta concentrazione SMT202000095T1 (it)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33498610P	2010-05-14	2010-05-14
EP17158990.6A EP3195880B1 (en)	2010-05-14	2011-05-11	High concentration anti-sclerostin antibody formulations

Publications (1)

Publication Number	Publication Date
SMT202000095T1 true SMT202000095T1 (it)	2020-03-13

Family

ID=44146975

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SM20200095T SMT202000095T1 (it)	2010-05-14	2011-05-10	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
SM20250009T SMT202500009T1 (it)	2010-05-14	2011-05-11	Formulazioni di anticorpi ad alta concentrazione
SM20170252T SMT201700252T1 (it)	2010-05-14	2011-05-11	Formulazioni di anticorpi ad alta concentrazione

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SM20250009T SMT202500009T1 (it)	2010-05-14	2011-05-11	Formulazioni di anticorpi ad alta concentrazione
SM20170252T SMT201700252T1 (it)	2010-05-14	2011-05-11	Formulazioni di anticorpi ad alta concentrazione

Country Status (31)

Country	Link
US (4)	US9352043B2 (it)
EP (4)	EP2569010B1 (it)
JP (6)	JP5889877B2 (it)
KR (3)	KR101861867B1 (it)
CN (1)	CN102946903B (it)
AU (1)	AU2011250920B2 (it)
BR (1)	BR112012028920B1 (it)
CA (1)	CA2798888C (it)
CL (1)	CL2012003172A1 (it)
CO (1)	CO6640258A2 (it)
CY (2)	CY1119069T1 (it)
DK (3)	DK3195880T3 (it)
EA (3)	EA037392B1 (it)
ES (3)	ES3008262T3 (it)
FI (1)	FI3620175T3 (it)
HN (1)	HN2012002446A (it)
HR (3)	HRP20170983T1 (it)
HU (3)	HUE069682T2 (it)
IL (3)	IL264636B (it)
LT (3)	LT3620175T (it)
ME (1)	ME02819B (it)
MX (1)	MX2012013268A (it)
PL (3)	PL3620175T3 (it)
PT (3)	PT2569010T (it)
RS (3)	RS59993B1 (it)
SG (3)	SG10201912670XA (it)
SI (3)	SI3195880T1 (it)
SM (3)	SMT202000095T1 (it)
TW (4)	TWI617570B (it)
WO (1)	WO2011143307A1 (it)
ZA (1)	ZA201208543B (it)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040002451A1 (en) *	2002-06-20	2004-01-01	Bruce Kerwin	Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
CA2680237C (en)	2007-03-27	2018-11-06	Sea Lane Biotechnologies, Llc	Constructs and libraries comprising antibody surrogate light chain sequences
US20120128671A1 (en)	2009-05-13	2012-05-24	Lawrence Horowitz	Neutralizing molecules to influenza viruses
SMT202000095T1 (it) *	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2013016714A1 (en)	2011-07-28	2013-01-31	Sea Lane Biotechnologies	Sur-binding proteins against erbb3
US9975956B2 (en)	2011-12-22	2018-05-22	I2 Pharmaceuticals, Inc.	Surrogate binding proteins which bind DR4 and/or DR5
EA202091676A1 (ru) *	2011-12-28	2021-01-29	Эмджен Инк.	Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201590061A1 (ru) *	2012-06-21	2015-05-29	Юсб Фарма С.А.	Фармацевтическая композиция
FR2994390B1 (fr)	2012-08-10	2014-08-15	Adocia	Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
IL312865B2 (en) *	2013-09-11	2025-06-01	Eagle Biologics Inc	Liquid protein formulations containing viscosity-lowering agents
US11357857B2 (en)	2014-06-20	2022-06-14	Comera Life Sciences, Inc.	Excipient compounds for protein processing
US20160074515A1 (en)	2014-06-20	2016-03-17	Reform Biologics, Llc	Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en)	2014-06-20	2019-11-19	Reform Biologics, Llc	Excipient compounds for biopolymer formulations
EP3240566B1 (en) *	2014-12-31	2020-07-22	Development Center for Biotechnology	Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
US9527922B2 (en)	2014-12-31	2016-12-27	Development Center For Biotechnology	Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
WO2017057644A1 (ja) *	2015-09-30	2017-04-06	持田製薬株式会社	高濃度抗体含有液体製剤
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
JP7114567B2 (ja) *	2016-08-17	2022-08-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	生体分子を含む高濃縮液体製剤の調製のためのプロセス
WO2018115879A1 (en)	2016-12-21	2018-06-28	Mereo Biopharma 3 Limited	Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US11840565B2 (en)	2016-12-29	2023-12-12	University Of Miami	Methods and compositions for treating virus-associated inflammation
WO2018126009A1 (en)	2016-12-29	2018-07-05	University Of Miami	Method for modulating inflammasome activity and inflammation in the lung
WO2018211517A1 (en)	2017-05-16	2018-11-22	Bhami's Research Laboratory, Pvt. Ltd.	High concentration protein formulations with reduced viscosity
US11590237B2 (en) *	2017-05-18	2023-02-28	Merck Sharp & Dohme Llc	Pharmaceutical formulation comprising incretin-insulin conjugates
CN109952093B (zh) *	2017-07-27	2022-02-08	江苏恒瑞医药股份有限公司	一种sost抗体药物组合物及其用途
GB201719447D0 (en) *	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
JP6544669B1 (ja)	2018-03-16	2019-07-17	ディヴェロップメントセンターフォーバイオテクノロジー	アルファエノラーゼに特異的な抗体及びその使用
KR20200138254A (ko) *	2018-03-30	2020-12-09	암젠 인크	C-말단 항체 변이체
SG11202013176VA (en) *	2018-07-03	2021-01-28	Univ Miami	Compositions and methods for treating inflammasome related diseases or conditions
AU2019314355B2 (en) *	2018-07-31	2025-05-15	Amgen Inc.	Pharmaceutical formulations of masked antibodies
CA3108693A1 (en) *	2018-08-10	2020-02-13	Ashutosh Sharma	Method of preparing an antibody pharmaceutical formulation
KR102735988B1 (ko)	2019-02-18	2024-12-03	일라이 릴리 앤드 캄파니	치료 항체 제제
CN115279404A (zh) *	2020-02-13	2022-11-01	安进公司	人抗tslp抗体的配制品及治疗炎性疾病的方法
CN114703067B (zh) *	2022-04-06	2023-09-05	上海光玥生物科技有限公司	一种光合微生物及其用途和质粒

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4411993A (en)	1981-04-29	1983-10-25	Steven Gillis	Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en)	1981-10-19	1984-01-24	Laipply Thomas C	One piece alcohol preparation device
JPS5889877A (ja)	1981-11-21	1983-05-28	Nippon Telegr & Teleph Corp <Ntt>	超伝導回路装置
USRE32011E (en)	1981-12-14	1985-10-22	Scripps Clinic And Research Foundation	Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en)	1982-12-13	1985-09-24	Massachusetts Institute Of Technology	Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de)	1984-05-11	1986-01-09	Matter + Siegmann Ag, Wohlen	Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en)	1984-12-03	1990-02-20	Teijin Limited	Monoclonal antibody to human protein C
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5177197A (en)	1990-02-27	1993-01-05	Ludwig Institute For Cancer Research	Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
JPH04141095A (ja)	1990-10-02	1992-05-14	Chemo Sero Therapeut Res Inst	組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en)	1990-10-12	1991-12-03	Trustees Of The University Of Pennsylvania	Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en)	1990-10-22	1992-04-30	Fox Chase Cancer Center	Dna construct for providing rna therapy
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5795965A (en)	1991-04-25	1998-08-18	Chugai Seiyaku Kabushiki Kaisha	Reshaped human to human interleukin-6 receptor
EP1136556B1 (en)	1991-11-25	2005-06-08	Enzon, Inc.	Method of producing multivalent antigen-binding proteins
US5864027A (en)	1993-06-07	1999-01-26	Genentech, Inc.	HIV envelope polypeptides
US5543158A (en)	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5453492A (en)	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
WO1995030003A2 (en)	1994-04-29	1995-11-09	Creative Biomolecules, Inc.	Morphogenic protein-specific cell surface receptors and uses therefor
DE4427221A1 (de)	1994-08-01	1996-02-08	Gsf Forschungszentrum Umwelt	Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en)	1994-11-22	1998-12-08	Genetics Institute, Inc.	DNA molecules encoding human chordin
US6057421A (en)	1994-11-30	2000-05-02	Immpheron, Inc.	Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en)	1995-04-04	1998-07-29	Elan Corp Plc	Controlled release biodegradable nanoparticles containing insulin
WO1996039486A1 (en)	1995-06-05	1996-12-12	Human Genome Sciences, Inc.	Human ccn-like growth factor
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
BR9710811A (pt)	1996-05-22	1999-08-17	Novopharm Biotech Inc	Fragmentos de liga-Æo de antigeno que detecta especificamente c-lulas cancerigenas nucleotideos que codificam os fragmentos e o seu uso para a profilaxia e detec-Æo de c-nceres
US6133426A (en)	1997-02-21	2000-10-17	Genentech, Inc.	Humanized anti-IL-8 monoclonal antibodies
US5989909A (en)	1997-09-26	1999-11-23	Millennium Biotherapeutics, Inc.	Huchordin and uses thereof
AU6959898A (en)	1997-04-11	1998-11-11	David J. Grainger	Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
EP1958962A3 (en)	1997-06-12	2013-05-01	Novartis International Pharmaceutical Ltd.	Artificial antibody polypeptides
US6075007A (en)	1997-07-17	2000-06-13	Regeneron Pharmaceuticals, Inc.	Modified noggin polypeptide and compositions
CA2297109A1 (en)	1997-08-01	1999-02-11	Genset	5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en)	1997-09-08	2004-11-09	The Public Health Research Institute Of The City Of New York, Inc.	HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
US6544485B1 (en)	2001-01-29	2003-04-08	Sharper Image Corporation	Electro-kinetic device with enhanced anti-microorganism capability
US6395511B1 (en)	1998-11-27	2002-05-28	Darwin Discovery, Ltd.	Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
CA2361553A1 (en)	1999-01-29	2000-08-03	Zhenping Zhu	Antibodies specific to kdr and uses thereof
EP1185642A2 (en)	1999-06-09	2002-03-13	Genentech, Inc.	Compositions and methods for the treatment of tumor
US6475220B1 (en)	1999-10-15	2002-11-05	Whiteside Biomechanics, Inc.	Spinal cable system
JP4141095B2 (ja)	1999-10-29	2008-08-27	三洋電機株式会社	半導体装置とその製造方法
AU2001241968B2 (en)	2000-03-02	2005-09-15	Amgen Inc.	Chordin-like-2 molecules and uses thereof
MXPA02011808A (es)	2000-06-01	2003-04-10	Amgen Inc	Polipeptidos de nudos de cistinas: moleculas de polipeptidos encubierto-2 y usos de los mismos.
US20040132021A1 (en)	2000-06-19	2004-07-08	Wendy Balemans	Osteolevin gene polymorphisms
CA2421056A1 (en)	2000-09-01	2002-03-28	Genentech, Inc.	A polypeptide for use as a diagnostic marker for the presence of colon tumours
ES2332402T5 (es) *	2000-10-12	2018-05-14	Genentech, Inc.	Formulaciones de proteína concentradas de viscosidad reducida
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en)	2001-03-13	2002-09-13	The Minister Of National Defence	Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
EP1433793A4 (en)	2001-09-13	2006-01-25	Inst Antibodies Co Ltd	METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
DE10145772A1 (de)	2001-09-17	2003-04-10	Bayer Cropscience Ag	DELTA·1·-Pyrroline
AU2002357107B2 (en)	2001-12-06	2008-01-10	Biocontrol Systems, Inc.	Sample collection and testing system
US20030186915A1 (en)	2002-02-11	2003-10-02	Yang Pan	Regulatory polynucleotides and uses thereof
EP1575481A4 (en)	2002-03-01	2010-01-06	Celltech R & D Inc	PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
WO2003087763A2 (en)	2002-04-03	2003-10-23	Celltech R & D, Inc.	Association of polymorphisms in the sost gene region with bone mineral density
US7893218B2 (en)	2003-06-16	2011-02-22	Stowers Institute For Medical Research	Antibodies that specifically bind SOST peptides
WO2003106657A2 (en)	2002-06-14	2003-12-24	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
EP1551875A4 (en) *	2002-06-21	2006-06-28	Biogen Idec Inc	TAMPON PREPARATIONS FOR CONCENTRATING ANTIBODIES AND METHODS FOR USE THEREOF
WO2004039337A2 (en)	2002-10-31	2004-05-13	Protein Design Labs, Inc.	Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
CA2504493C (en)	2002-11-01	2015-12-29	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides
US7642238B2 (en)	2002-12-05	2010-01-05	Shaughnessy John D	Molecular determinants of myeloma bone disease and uses thereof
US20040141875A1 (en)	2003-01-15	2004-07-22	Rajiv Doshi	System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
PL378566A1 (pl)	2003-03-14	2006-05-02	Celltech R & D, Inc.	Ligandy dla białek wiążących TGF-beta i ich zastosowania
US20050158303A1 (en) *	2003-04-04	2005-07-21	Genentech, Inc.	Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es)	2003-04-23	2009-08-04	Centro Inmunologia Molecular	Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1636270B1 (en)	2003-06-16	2016-07-20	UCB Pharma S.A.	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US20050267233A1 (en)	2004-05-25	2005-12-01	Joshi Ashok V	Anti-microbial handle system
MX2007001221A (es)	2004-08-04	2007-03-23	Amgen Inc	Anticuerpos para proteina dickkopf-1 (dkk-1).
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
WO2007076062A2 (en)	2005-12-21	2007-07-05	Wyeth	Protein formulations with reduced viscosity and uses thereof
EP1981910B1 (en)	2006-01-13	2013-06-26	A Chan Holding B.V.	Method for identifying inhibitor of the glypican-sclerostin interaction
EP2094731A2 (en)	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
WO2008061013A2 (en)	2006-11-10	2008-05-22	Amgen Inc.	Antibody-based diagnostics and therapeutics
US8178099B2 (en)	2006-12-29	2012-05-15	Osteogenex Inc.	Methods of altering bone growth by administration of sost or wise antagonist or agonist
JP2010526766A (ja)	2007-02-02	2010-08-05	ノバルティスアーゲー	骨関連障害を処置するためのスクレロスチン結合パートナーのモジュレーター
CN101646457B (zh)	2007-03-20	2013-05-01	伊莱利利公司	抗硬骨素抗体
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
WO2009056634A2 (en)	2007-11-02	2009-05-07	Novartis Ag	Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
BRPI0819688A2 (pt)	2007-12-14	2015-06-16	Amgen Inc	Processo para tratamento de fratura óssea com anticorpos anti-esclerostina.
EP2285401A1 (en) *	2008-05-23	2011-02-23	Novo Nordisk Health Care AG	Low viscosity compositions comprising a pegylated gla-domain containing protein
BRPI0913406A2 (pt)	2008-06-03	2018-01-09	Abbott Lab	imunoglobulinas de domínio variável duplo e usos das mesmas
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2010100200A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Lyophilised antibody formulation
WO2010115932A1 (en)	2009-04-08	2010-10-14	Novartis Ag	Combination for the treatment of bone loss
WO2010130830A2 (en)	2009-05-15	2010-11-18	Ablynx N.V.	Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
SMT202000095T1 (it) *	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery
EP2632951B1 (en)	2010-10-27	2017-08-02	Amgen Inc.	Dkk1 antibodies and methods of use
KR101962483B1 (ko) *	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
US8790651B2 (en) *	2011-07-21	2014-07-29	Zoetis Llc	Interleukin-31 monoclonal antibody

2011
- 2011-05-10 SM SM20200095T patent/SMT202000095T1/it unknown
- 2011-05-11 EP EP11720278.8A patent/EP2569010B1/en active Active
- 2011-05-11 US US13/702,658 patent/US9352043B2/en active Active
- 2011-05-11 EP EP17158990.6A patent/EP3195880B1/en active Active
- 2011-05-11 KR KR1020127032558A patent/KR101861867B1/ko active Active
- 2011-05-11 HU HUE19202835A patent/HUE069682T2/hu unknown
- 2011-05-11 EP EP24198927.6A patent/EP4483901A3/en active Pending
- 2011-05-11 MX MX2012013268A patent/MX2012013268A/es active IP Right Grant
- 2011-05-11 DK DK17158990.6T patent/DK3195880T3/da active
- 2011-05-11 HU HUE11720278A patent/HUE033315T2/en unknown
- 2011-05-11 SI SI201131842T patent/SI3195880T1/sl unknown
- 2011-05-11 PT PT117202788T patent/PT2569010T/pt unknown
- 2011-05-11 RS RS20200217A patent/RS59993B1/sr unknown
- 2011-05-11 DK DK11720278.8T patent/DK2569010T3/en active
- 2011-05-11 DK DK19202835.5T patent/DK3620175T3/da active
- 2011-05-11 EA EA201692242A patent/EA037392B1/ru not_active IP Right Cessation
- 2011-05-11 CA CA2798888A patent/CA2798888C/en active Active
- 2011-05-11 CN CN201180023921.4A patent/CN102946903B/zh active Active
- 2011-05-11 KR KR1020187014175A patent/KR102026038B1/ko active Active
- 2011-05-11 HR HRP20170983TT patent/HRP20170983T1/hr unknown
- 2011-05-11 EA EA202092884A patent/EA202092884A1/ru unknown
- 2011-05-11 RS RS20241450A patent/RS66360B1/sr unknown
- 2011-05-11 PL PL19202835.5T patent/PL3620175T3/pl unknown
- 2011-05-11 EA EA201291226A patent/EA027039B1/ru not_active IP Right Cessation
- 2011-05-11 PL PL17158990T patent/PL3195880T3/pl unknown
- 2011-05-11 JP JP2013510274A patent/JP5889877B2/ja active Active
- 2011-05-11 KR KR1020197027464A patent/KR102220879B1/ko active Active
- 2011-05-11 PT PT192028355T patent/PT3620175T/pt unknown
- 2011-05-11 FI FIEP19202835.5T patent/FI3620175T3/fi active
- 2011-05-11 AU AU2011250920A patent/AU2011250920B2/en active Active
- 2011-05-11 SG SG10201912670XA patent/SG10201912670XA/en unknown
- 2011-05-11 SG SG10201701869YA patent/SG10201701869YA/en unknown
- 2011-05-11 LT LTEP19202835.5T patent/LT3620175T/lt unknown
- 2011-05-11 SG SG2012082202A patent/SG185465A1/en unknown
- 2011-05-11 SM SM20250009T patent/SMT202500009T1/it unknown
- 2011-05-11 BR BR112012028920-9A patent/BR112012028920B1/pt active IP Right Grant
- 2011-05-11 IL IL264636A patent/IL264636B/en unknown
- 2011-05-11 LT LTEP11720278.8T patent/LT2569010T/lt unknown
- 2011-05-11 HR HRP20250025TT patent/HRP20250025T1/hr unknown
- 2011-05-11 LT LTEP17158990.6T patent/LT3195880T/lt unknown
- 2011-05-11 ES ES19202835T patent/ES3008262T3/es active Active
- 2011-05-11 SI SI201132124T patent/SI3620175T1/sl unknown
- 2011-05-11 WO PCT/US2011/036062 patent/WO2011143307A1/en not_active Ceased
- 2011-05-11 PL PL11720278T patent/PL2569010T3/pl unknown
- 2011-05-11 ES ES17158990T patent/ES2773031T3/es active Active
- 2011-05-11 EP EP19202835.5A patent/EP3620175B1/en active Active
- 2011-05-11 ES ES11720278.8T patent/ES2626033T3/es active Active
- 2011-05-11 PT PT171589906T patent/PT3195880T/pt unknown
- 2011-05-11 HU HUE17158990A patent/HUE047492T2/hu unknown
- 2011-05-11 SM SM20170252T patent/SMT201700252T1/it unknown
- 2011-05-11 ME MEP-2017-147A patent/ME02819B/me unknown
- 2011-05-11 RS RS20170674A patent/RS56210B1/sr unknown
- 2011-05-11 SI SI201131181T patent/SI2569010T1/sl unknown
- 2011-05-13 TW TW100116950A patent/TWI617570B/zh active
- 2011-05-13 TW TW111107371A patent/TWI871502B/zh active
- 2011-05-13 TW TW108135531A patent/TWI759634B/zh active
- 2011-05-13 TW TW105120111A patent/TWI689517B/zh active
2012
- 2012-11-12 CL CL2012003172A patent/CL2012003172A1/es unknown
- 2012-11-13 IL IL223014A patent/IL223014B/en active IP Right Grant
- 2012-11-13 ZA ZA2012/08543A patent/ZA201208543B/en unknown
- 2012-11-13 HN HN2012002446A patent/HN2012002446A/es unknown
- 2012-12-03 CO CO12218641A patent/CO6640258A2/es unknown
2016
- 2016-02-17 JP JP2016027699A patent/JP6174176B2/ja active Active
- 2016-05-02 US US15/144,256 patent/US10064946B2/en active Active
2017
- 2017-05-25 CY CY20171100542T patent/CY1119069T1/el unknown
- 2017-07-05 JP JP2017131572A patent/JP6416336B2/ja active Active
2018
- 2018-07-26 US US16/045,928 patent/US11040102B2/en active Active
- 2018-10-03 JP JP2018187831A patent/JP7267707B2/ja active Active
2020
- 2020-02-17 CY CY20201100145T patent/CY1122669T1/el unknown
- 2020-02-18 HR HRP20200268TT patent/HRP20200268T1/hr unknown
2021
- 2021-05-21 US US17/326,725 patent/US12178873B2/en active Active
- 2021-09-13 JP JP2021148735A patent/JP2022000436A/ja not_active Withdrawn
2022
- 2022-08-02 IL IL295275A patent/IL295275B1/en unknown
2023
- 2023-09-29 JP JP2023169763A patent/JP7675774B2/ja active Active

Also Published As

Publication number	Publication date
JP2016138110A (ja)	2016-08-04
JP2013527176A (ja)	2013-06-27
PT2569010T (pt)	2017-05-31
US11040102B2 (en)	2021-06-22
ES3008262T3 (en)	2025-03-21
KR20190109600A (ko)	2019-09-25
HUE033315T2 (en)	2017-11-28
WO2011143307A1 (en)	2011-11-17
BR112012028920B1 (pt)	2021-03-23
EA027039B1 (ru)	2017-06-30
KR20180056803A (ko)	2018-05-29
IL223014A0 (en)	2013-02-03
AU2011250920B2 (en)	2015-05-21
JP6416336B2 (ja)	2018-10-31
CO6640258A2 (es)	2013-03-22
EP2569010B1 (en)	2017-04-12
LT3620175T (lt)	2025-01-27
SG185465A1 (en)	2012-12-28
TWI759634B (zh)	2022-04-01
HUE069682T2 (hu)	2025-04-28
TW202017941A (zh)	2020-05-16
EA037392B1 (ru)	2021-03-23
CY1119069T1 (el)	2018-01-10
SG10201912670XA (en)	2020-02-27
IL264636B (en)	2022-09-01
IL295275B1 (en)	2025-12-01
JP2022000436A (ja)	2022-01-04
EP3195880A1 (en)	2017-07-26
EP3620175B1 (en)	2024-10-16
PL2569010T3 (pl)	2017-09-29
CY1122669T1 (el)	2021-03-12
SI3195880T1 (sl)	2020-03-31
DK3195880T3 (da)	2020-03-02
TWI689517B (zh)	2020-04-01
LT3195880T (lt)	2020-01-10
ES2626033T3 (es)	2017-07-21
FI3620175T3 (fi)	2025-01-13
JP7267707B2 (ja)	2023-05-02
SI3620175T1 (sl)	2025-03-31
HRP20200268T1 (hr)	2020-05-29
US20160235849A1 (en)	2016-08-18
CA2798888A1 (en)	2011-11-17
TW201144326A (en)	2011-12-16
PT3195880T (pt)	2020-02-21
EP3620175A1 (en)	2020-03-11
HRP20170983T1 (hr)	2017-09-22
ES2773031T3 (es)	2020-07-09
RS59993B1 (sr)	2020-04-30
IL295275A (en)	2022-10-01
HRP20250025T1 (hr)	2025-03-14
US12178873B2 (en)	2024-12-31
RS66360B1 (sr)	2025-01-31
PL3620175T3 (pl)	2025-03-10
TWI871502B (zh)	2025-02-01
JP2023182702A (ja)	2023-12-26
EP3195880B1 (en)	2019-11-27
PT3620175T (pt)	2025-01-14
KR20130117650A (ko)	2013-10-28
JP2019031515A (ja)	2019-02-28
LT2569010T (lt)	2017-08-10
EA201291226A1 (ru)	2013-04-30
DK3620175T3 (da)	2025-01-06
AU2011250920A1 (en)	2012-12-20
SMT202500009T1 (it)	2025-03-12
ME02819B (me)	2018-01-20
EA201692242A1 (ru)	2017-11-30
EA202092884A1 (ru)	2022-01-31
ZA201208543B (en)	2021-10-27
EP4483901A3 (en)	2025-03-19
JP5889877B2 (ja)	2016-03-30
EP4483901A2 (en)	2025-01-01
HUE047492T2 (hu)	2020-04-28
CN102946903A (zh)	2013-02-27
US9352043B2 (en)	2016-05-31
KR101861867B1 (ko)	2018-05-29
US20130202620A1 (en)	2013-08-08
US10064946B2 (en)	2018-09-04
IL223014B (en)	2019-02-28
TW201706304A (zh)	2017-02-16
US20190022230A1 (en)	2019-01-24
CA2798888C (en)	2019-10-01
JP2017222674A (ja)	2017-12-21
HN2012002446A (es)	2015-08-03
SI2569010T1 (sl)	2017-09-29
BR112012028920A2 (pt)	2017-03-14
SMT201700252T1 (it)	2017-09-07
RS56210B1 (sr)	2017-11-30
CN102946903B (zh)	2014-11-26
KR102220879B1 (ko)	2021-02-26
DK2569010T3 (en)	2017-06-26
JP6174176B2 (ja)	2017-08-02
EP2569010A1 (en)	2013-03-20
JP7675774B2 (ja)	2025-05-13
TW202241510A (zh)	2022-11-01
KR102026038B1 (ko)	2019-09-26
TWI617570B (zh)	2018-03-11
US20210275671A1 (en)	2021-09-09
MX2012013268A (es)	2013-05-28
CL2012003172A1 (es)	2013-11-29
PL3195880T3 (pl)	2020-06-01
SG10201701869YA (en)	2017-04-27
IL264636A (it)	2019-03-31

Publication	Publication Date	Title
IL295275B1 (en)	2025-12-01	High concentration antibody formulations
IL276234B (en)	2022-04-01	Antibody compositions
IL226217A0 (en)	2013-07-31	Improved liquid preparations with פריקוע@גבוה@של@אנטיטן@אנטי@α–tnf
ZA201608660B (en)	2018-05-30	Anti - sclerostin antibody crystals and formulations thereof
PL3117837T3 (pl)	2020-02-28	Formulacje przeciwciała
IL232213B (en)	2019-03-31	Antibody Formulations and Methods
EP2588141A4 (en)	2014-12-03	ANTIBODY FORMULATIONS